[Early results of topotecan therapy in patients with recurrent ovarian cancer].
BACKGROUND
Topotecan inhibits the topoisomerase-I enzyme resulting its stabilisation on the DNA and the suspension of replication and transcription.


OBJECTIVE
The authors summarized their first experience on second-line topotecan treatment in a prospective non-randomized study.


METHODS
Topotecan was given for recurrent epithelial ovarian cancer in the dose of 1.5 mg/m2/d for 5 days repeated in every 3 weeks in a 30-minute infusion intravenously.


RESULTS
Twenty five recurrent ovarian cancer patients were treated between March, 1999 and March, 2001. Complete and partial response rates were found 12% and 12%, respectively. Stable disease was observed in 48% of patients for 4-8 courses, then progression continued. In these 3 groups of patients the median progression free interval was shown as 12 weeks.


CONCLUSIONS
When comparing to previous chemotherapies, topotecan treatment failed to show a definitive improvement in the outcome of recurrent ovarian cancer.
Lehoczky
Ottó
O
Nógyógyászati Onkológiai Osztály, Országos Onkológiai Intézet, Budapest. lehoczky@oncol.hu
Bagaméri
Andrea
A
Lehoczky
Gyózó
G
Pulay
Tamás
T
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D011446:Prospective Studies; D059004:Topoisomerase I Inhibitors; D019772:Topotecan / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D059004:Topoisomerase I Inhibitors; D019772:Topotecan
Kiújult petefészekrák topotecankezelésével szerzett korai tapasztalatok.